Cargando…
Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging
The leucine-rich repeat kinase 2 mutation G2019S in the kinase-domain is the most common genetic cause of Parkinson's disease. To investigate the impact of the G2019S mutation on motor activity in vivo, a longitudinal phenotyping approach was developed in knock-in (KI) mice bearing this kinase-...
Autores principales: | Longo, Francesco, Russo, Isabella, Shimshek, Derya R., Greggio, Elisa, Morari, Michele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academic Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4194318/ https://www.ncbi.nlm.nih.gov/pubmed/25107341 http://dx.doi.org/10.1016/j.nbd.2014.07.013 |
Ejemplares similares
-
Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice
por: Longo, Francesco, et al.
Publicado: (2017) -
Leucine‐rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes
por: Mercatelli, Daniela, et al.
Publicado: (2019) -
LRRK2 and neuroinflammation: partners in crime in Parkinson’s disease?
por: Russo, Isabella, et al.
Publicado: (2014) -
LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex
por: Cirnaru, Maria D., et al.
Publicado: (2014) -
LRRK2 modulates neuronal vesicles cycle through protein interactions
por: Piccoli, Giovanni, et al.
Publicado: (2015)